
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Rare Skin Disorder
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has completed TOIVA, its Phase 2 clinical trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel as a potential treatment for cutaneous venous malformations …
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Rare Skin Disorder Read More